Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026
Is It Too Late To Consider Mineralys Therapeutics After Its Huge 2025 Share Price Surge [Yahoo! Finance]
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow [Yahoo! Finance]
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears [Yahoo! Finance]
Mineralys Therapeutics (NASDAQ:MLYS) was given a new $52.00 price target on by analysts at Stifel Nicolaus. They now have a "buy" rating on the stock.